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Abstract 
Other than an association with HPV infection, little is known about the genetic alterations 
determining the development of penile cancer (PeCa). While PeCa is rare in the developed 
world, it presents a significant burden in developing countries. Here we report the findings 
of whole exome sequencing (WES) to determine the somatic mutational landscape of PeCa. 
WES was performed on PeCa and matched germline DNA from 27 patients undergoing 
surgical resection. Targeted resequencing of candidate genes was performed in an 
independent 70 patient cohort. Mutation data was also integrated with DNA methylation 
and copy number information from the same patients. We identified an HPV-associated 
APOBEC mutation signature and a NpCpG signature in HPV-negative disease. We also 
identified recurrent mutations in the novel PeCa tumor suppressor genes CSN1(GPS1) and 
FAT1. Expression of CSN1 mutants in cells resulted in co-localization with AGO2 in 
cytoplasmic P-bodies, ultimately leading to the loss of miRNA-mediated gene silencing which 
may contribute to disease etiology. Our findings represent the first comprehensive analysis 
of somatic alterations in PeCa, highlighting the complex landscape of alterations in this 
malignancy.  
  
 
 
 
 
 
 
 
 
 
Introduction 
The aetiology of Penile Cancer (PeCa) is multifactorial with smoking, phimosis, poor personal 
hygiene and low socioeconomic status all being risk factors for tumour development(1). 
However, other than the oncogenic impact of high risk human papillomavirus (HPV) 
infection, which is responsible for ~30% of penile cancers, little is known about the 
molecular alterations involved in the development of this disease.  
 
 PeCa is relatively rare in the developed world, but represents a global health problem, with 
high prevalence and significant associated morbidity and mortality in developing 
countries(1, 2). The age standardised incidence of PeCa is 0.3-1.0 per 100,000 men in 
European countries and the United States, equating to approximately 1600 new cases per 
annum in the USA (3). In contrast, the incidence in developing nations varies from 3 to 8.3 
per 100,000(3). Five year survival is between 50% and 80% dependent on tumour stage and 
age at presentation, and over 40% of patients present with lymph node metastases(2). 
 
We have previously reported genome-wide epigenetic events involved in an aggressive 
penile cancer phenotype and identified potential epigenetic drivers of penile cancer(4). In 
this study, we sought to determine the genetic component involved in PeCa development, 
by performing the first whole exome sequencing (WES) analysis of PeCa to identify the 
somatic alterations.  
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Methods 
Sample Cohort. Samples were collected from PeCa patients at UCLH NHS Trust, UK. 
Informed consent was obtained from all subjects and ethical approval for this study was 
granted by the University College London (UCL) / University College London Hospital (UCLH) 
BioBank for Health and Human Disease (NC06.11). All samples were reviewed by a 
consultant histopathologist and confirmed to be ≥80% tumour content. The samples have 
previously been reported in other studies(4). The histological characteristics of our discovery 
and validation cohorts are shown in Supplementary Table 1. 
 
Whole-exome sequencing. Exome capture was performed using 50ng of tumour or matched 
germline DNA. Library preparation was performed using the Illumina TrueSeq or Nextrea 
exome capture kit according to the manufactures guidelines (Ilumina, San Diego, CA, USA). 
Samples underwent paired end sequencing on a Hi-Seq2000 platform with 100bp read 
length to a mean coverage of 60X. Validation samples were subjected to targeted 
sequencing candidate genes (CSN1/GPS1, FAT1 and TP53) using Fluidigm custom 
amplification. A mean coverage of 156x was achieved across the validation cohort. Detailed 
methods for sequencing analysis can be found in the Supplementary Methods.  
 
Sequencing data has been submitted to European Genome-phenome Archive (EGA) 
(accession number pending). Access requests are through the UCL CI the Population and 
Medical Genomics Data Access Committee (DAC). 
 
Variant Detection. The Varscan (Koboldt et al., 2012) algorithm (v2.2.10, 
varscan.sourceforge.net) was used to call both single nucleotide alterations and indels. 
Alterations were annotated to the Human reference genome, version 38, using 
Annovar(Wang et al., 2010) (v.517, http://www.openbioinformatics.org/annovar/). SNPs 
were annotated using Oncotator from the Broad Institute 
(http://www.broadinstitute.org/oncotator/). Common germline SNPs as recorded in 
either dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), 1000 genomes 
(http://www.1000genomes.org) were excluded from further analysis. Germline SNP analysis 
was used to confirm sample identify between tumour and normal pairs. Significantly 
mutated genes were defined as genes with recurrent mutations that showed a functional 
mutation bias q.value of 0.1 or less following analysis by the IntOgen mutation analysis 
platform (Gonzalez-Perez et al., 2013). Mutations in potential candidate drivers were 
visualized after filtering for genes not in the MutSig5000 set of pan-tissue cancer associated 
genes (Lawrence et al., 2014).  
 
Annotation and visualisation of mutations. SNPs were annotated using Oncotator from the 
Broad Institute http://www.broadinstitute.org/oncotator/. Significantly mutated genes were 
defined as genes with recurrent mutations that showed a functional mutation bias q.value of 
0.1 or less following analysis by the IntOgen mutation analysis platform (Gonzalez-Perez et 
al., 2013). Mutations in potential candidate drivers were visualised after filtering for genes 
not in the MutSig5000 set of pan-tissue cancer associated genes (Lawrence et al., 2014).  
 
Pathway analysis. Pathway analysis was performed using IntOgen pathway analysis[15]. 
Significantly mutated KEGG pathways were identified using IntOgen pathway analysis based 
on functional mutation bias with a Q.value of less than 0.05. Selected coding mutations were 
visualized in the context of cancer associated pathways.   
 
Supervised Analysis of potential deamination signatures. Overall mutational analysis was 
carried out by visualising the breakdown of mutations into 12 categories of base changes. A 
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high proportion of mutations were C>T or G>A, which were candidate cytosine deamination 
events. In order to examine the role of cytosine deamination mediated by the APOBEC 
family of cytosine deaminases and the spontaneous deamination of methylcytosines in 
contributing to the overall mutational burden of the tumour samples, supervised analysis 
was carried out to model mutagenesis as the fraction of all mutations in the tumour. 
Candidate APOBEC-induced mutations were defined as C->K changes in the TCW context on 
either strand where K=T/G, W=A/T while CpG deamination events were defined as C->T 
changes in the context of ACG/CCG/GCG[11]. TCG mutations weren't considered for analysis 
because of potential confounding between APOBEC-induced and CpG-deamination induced 
C->T mutations[12]. To test for associations between fractions of deamination mutations 
were carried out for CpG deamination mutations and TCW->TKW mutations by HPV status 
we performed a multivariate binomial regression of APOBEC and CpG deamination 
mutations. We regressed the fraction of TCW->TKW mutations and the A/C/G CG -> A/C/G 
TG mutations using a binomial glm with HPV status by viral load, age, stage and grade as 
potential explanatory variables. 
 
Unsupervised extraction of mutational signatures. Mutations were parsed into a mutation 
motif matrix using the SomaticSignatures R package. 100 runs of NMF using the brunet 
algorithm in the NMF R package were used to decompose the motif matrix into signatures 
and sample-exposures (basis and coefficient respectively) for 2-5 clusters. This was followed 
by selecting the number of signatures on the basis of maximum consensus silhouette and 
the cophenetic correlation coefficient.  2 signatures were chosen based on a high cophenetic 
correlation and maximum consensus silhouette width (Supplementary Figure 6). 
 
Analysis of enrichment for CpG deamination events amongst TP53 mutations.  Enrichment 
for CpG mutations in TP53 was carried out using binomial testing against a background 
probability distribution. The background distribution (under the null hypothesis of no 
enrichment) was defined to factor in the number of CpG and non-CpG sites in the longest 
TP53 transcript according to the IARC P53 database (123 and 3001) and the average CpG 
mutation fraction in the four TP53 mutant tumours normalised to the exome wide 
frequency of CpG sites.  
 
Viral Detection. HPV viral load was assessed in PeCa DNA using Q-PCR for low risk HPV 6 and 
11 and high risk HPV 16, 18 and 31 by qPCR. Primers and probes are listed in supplementary 
table 3. The reference genes GAPDH and ACTB were used to normalise all HPV Q-PCR 
reactions. High and low viral load cases were defined as >1 HPV copy / cell and <1 HPV copy 
per cell respectively. VirusSeq (odin.mdacc.tmc.edu/~xsu1/VirusSeq.html)(Chen et al., 2013) 
and ViralFusionSeq (v. vfs-2012-12-07, http://sourceforge.net/projects/viralfusionseq/)(Li 
et al., 2013) were used to identify HPV integration from exome sequencing data.  
 
DNA methylation analysis. DNA methylation and copy number data were analyzed as 
previously described (4).  
 
CSN1 mutations. Constructs expressing Flag-tagged wild-type GPS1 /CSN1 were a kind gift 
from Ning Wei (Yale University). Mutations in GPS1 /CSN1 were made using the Q5® Site-
directed Mutagenesis kit (NEB) and confirmed by sequencing. 
 
miRNA reporter assays. HeLa cells were transfected with wild-type or the indicated mutant 
CSN1 with Renilla reporter constructs using Fugene®6 transfection reagent (Promega). For 
miR-100 assays, the reporter construct contained miR-100 binding sites in the 3'UTR with 
seed sequence matches or mismatches. The Let-7 reporter construct contained seven 
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partially complementary let-7a sites. The activity of Renilla luciferase was assayed and 
normalized to firefly luciferase activity using the Dual-Luciferase® Reporter Assay system 
(Promega). The activity of the miR-100 reporter containing seed matches was compared to 
that of the reporter containing mismatches. For the let-7 reporter, the activity was 
compared to a reporter construct with no miRNA binding sites in the Renilla 3’UTR. 
 
Immunofluorescence. Hela cells were plated on to 13mm glass coverslips (VWR) and 
transfected with the indicated GPS1 /CSN1 expressing constructs using Jetprime® (Polyplus 
Transfection™). Cells were fixed in 4% PFA for five minutes at 37°C and post-fix 
permeabilised for 90 seconds using 0.25% Triton X-100/PBS. Cells were stained with anti-
Flag M2 (Sigma) and Alexa-Flour® conjugated secondary (Life Technologies). 
Results 
Mutational spectrum of PeCa 
Analysis revealed 810 genes containing somatic mutations among the 27 tumours (24 
tumour germline pairs, 3 single tumours), with a mean somatic mutation rate of 30 per 
tumour.  This represents 1.78 non-silent mutations per megabase (range 0.72-7.5), relatively 
low when compared with other adult tumours that have a similar overall Ti/Tv 
(Transition/Transversion) ratio(5). There was no significant association between mutational 
burden and tumour stage, grade, age, or overall HPV status, however when stratified for 
HPV viral load, high viral load tumours had a significantly lower mutational load (P<0.05) 
when compared to HPV negative (Figure 1).  
 
As mutational patterns can be indicative of specific mutagenic mechanisms driving 
tumourigenesis, we assessed if any mutational signatures exist within PeCa. We found C>T 
alterations to be the most frequent substitution type. C>T mutations at CpG sites are 
ubiquitously present in cancers across multiple tissue types(6) and have been linked to the 
spontaneous deamination of methylated cytosine (mCpG)(6). Active cytosine deamination 
mediated by one or more ‘TC-specific’ apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like (APOBEC3) has recently been implicated as a significant driver of C>T and 
C>G mutations in HPV-associated cancers(7, 8).  To distinguish between mutations caused 
by methyl-cytosine deamination and APOBEC-catalyzed cytosine deamination, we examined 
the trinucleotide sequence contexts within which these mutations occur. We considered C>T 
mutations occurring at VCG sites (where V represents A, C or G) as mCpG deamination 
events and C>K (where K represents T or G) mutations in the TCW context as APOBEC-
mediated(7, 8). Multivariate modeling implicated APOBEC-induced mutagenesis to be 
significantly different between HPV status and did not implicate clinical covariates and age 
as confounders (p < 2.2e-16). CpG mutations, were also associated with HPV status (HPV 
negative disease p =  4.10e-07 and low-copy HPV+ p=1.55e-07) (Figure 2, S1), but not with 
age, stage or grade.  
  
The potential association of HPV viral load and the APOBEC3 (A3) associated signature may 
help clarify the association of APOBEC-induced mutagenesis. Previously, a lack of correlation 
between expression of A3 family transcripts and the A3 signature was noted(8). Similarly, 
E6/E7 oncogene expression is correlated with neither the A3 signature nor with A3 
expression in HPV-associated tumours(7). These data further highlight the role of HPV 
integration in the aetiology of a subset of PeCa, and although we cannot rule out the 
potential oncogenic effect of a cleared HPV infection, the lack of A3 signature mutations in 
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HPV low/negative samples suggests mechanisms other than high risk HPV infection are 
responsible for the development of PeCa in a significant number of cases.   
 
A significant enrichment of C>T alterations at [A/C/G]CG dinucleotides was demonstrated in 
both HPV low and negative disease compared to HPV high. Besides deamination of 
methylated cytosine resulting in somatic mutation, it can also affect DNA methylation levels. 
We observe a significant (P< 0.001) decrease in DNA methylation in HPV low and negative 
samples compared to high viral load samples and matched normal both globally and over 
gene bodies (Figure S2). There is no difference in methylation (global, gene body or CpG 
island) between HPV high samples and matched normal tissue (Figure S2), and the effect 
persists when comparing aged matched cases.  CG deamination has been suggested to be a 
non-random enzyme-catalysed event rather than a spontaneous occurrence(9). Although 
the catalytic drivers of this non-random CG deamination have yet to be identified, both A3A 
and A3B have been shown to deaminate cytosines in a CpG context(10). Besides potentially 
effecting epigenetic regulation, this CG deamination process may generate mutations 
integral to the carcinogenic process(7), for example in TP53, where three quarters of 
somatic alterations in PeCa are CG deamination events (P<0.005).  
 
Somatic alterations in penile squamous cell carcinoma 
Recurrent somatic mutations in PeCa were catalogued in order to identify putative 
pathogenic drivers. Of the 810 mutated genes, only 137 (17%) were recurrent alterations; 
756 (93%) have previously been identified as mutated in other tumour types. The lack of 
significant overlap in recurrently mutated genes in our cohort suggests that many are likely 
passenger mutations(5).  
 
Of the private alterations (637/810) several have been identified as putative drivers in the 
pan-cancer analysis of 4742 cancers(11), and include tumour suppressors CDKN2A and NF1, 
oncogenes such as HRAS and potential therapeutic targets such as kinases FLT1 and TGFBR2. 
Due to the low rate of recurrent alterations, enrichment of somatic mutations in canonical 
pathways was assessed(12). The p53 signaling pathway was identified as the most 
significantly mutated pathway (P 5.37 ×10−5).  
 
In order to identify putative cancer drivers, mutations that were recurrent and showed 
significant functional mutation bias were characterized using IntOgen(12) (Figure 1, Figure 
S3). Recurrent mutations were identified in the tumour suppressor genes TP53 (4/27), FAT1 
(4/27) and the G-protein pathway suppressor CSN1(GPS1) (3/27) (Figure 1, Figure S3). 
Orthogonal validation by sanger sequencing confirmed 100% of TP53, FAT1 and CSN1 
mutations in the original cohort.  TP53, CNS1 and FAT1 were also analyzed in independent 
cohort of 70 PeCa (50 FFPE, 20 fresh) and found to be mutated in 19%, 17% and 14% 
respectively.  As matched germline DNA was only available for 20/70 of the validation 
cohort, the possibility that some of these potential inactivating mutations may result from 
germline alterations cannot be excluded, therefore only mutations that were predicted to be 
functionally deleterious were included. As we only observe mutation in a total of 18/97 
cases we also assessed if TP53 under goes significant disruption through changes in DNA 
methylation or genomic copy number. Only 3 cases exhibited genomic loss of TP53, none of 
which overlapped with those harboring mutation (although copy number neutral LOH can 
not be ruled out) and none showed significant changes in promoter methylation. This low 
TP53 mutation rate, suggests that disruption of p53 is a key feature in only a subset of 
PeCa(13).   
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Somatic CSN1 mutations result in aberrant miRNA processing  
Of the genes containing novel mutations, CSN1 is mutated in 11% of cases (Figure 1), with a 
single case harboring two CSN1 alterations. CSN1 is a suppressor of G-proteins and mitogen 
activated signal transduction, and is an essential part of the COP9 signalosome complex 
(CSN), involved in the regulation of stem cell self-renewal and 
differentiation(14).  Sequencing of an independent PeCa cohort demonstrated a 14% (10/70) 
frequency of mutation. CSN1 is also reported to be mutated at low frequency in several 
other tumour types(15), and although little is known about its role in cancer development, it 
may be involved in the suppression of the AP-1 transcription factor pathway(16) and inhibit 
JUN dependent transcription activity(17).  
 
As none of the alterations associated with CSN1 are predicted to be truncating, in order to 
assess their role we recapitulated the 4 mutations identified in the initial discovery cohort in 
vitro. Recapitulation of the CSN1 mutations resulted in the translocation of CSN1 to the 
cytoplasm and co-localization with Argonaute1 and Argonaute2-positive P-bodies (Figure 3). 
As the Argonaute (AGO) family of proteins are key components of the RNA-induced silencing 
complex (RISC) which mediates microRNA-dependent repression, we sought to assess if 
CSN1 mutation effected miRNA-mediated gene repression. Expression of CSN1 point 
mutants resulted in a significant (p< 0.005) inhibition of miRNA-mediated gene repression 
compared to wild type (Figure 3). The greatest effect was seen with mutations (D382H and 
M384I) in the PCI (Protease Component) domain of CSN1 (Figure 2&3); five of the ten 
alterations identified in the validation cohort were also located within the PCI domain.  
Additional candidate PeCa drivers  
Mutation of FAT1 has been reported in other cancer types, including head and neck 
squamous cell carcinoma, colon cancer and glioblastoma(18).  FAT1 mutation promotes 
tumourigenicity through deregulation of the Wnt signaling cascade promoting cell 
proliferation and tumour growth(18). Analysis of the validation cohort identified FAT1 
mutations in a further 17% of samples, in which stopgain mutations represent the most 
frequent alteration. Deletion of 4q35, the locus harboring FAT1, has also been frequently 
identified in human cancers(18). Integrated analysis of genomic and epigenomic data was 
therefore performed to assess if FAT1 is disrupted by changes in genomic copy number or 
DNA methylation. No changes in copy number were observed, however, increased FAT1 
promoter methylation (compared with normal penile squamous epithelium) was observed in 
a further 20% of cases lacking mutation (Figure S4). These data indicate FAT1 is potentially 
deregulated in up to 37% of PeCa, and suggests FAT1 to be a key tumour suppressor in 
penile cancer development.  
Discussion  
The genetic and epigenetic mechanisms driving the development of PeCa are poorly 
understood. Through whole exome sequencing we have performed the most comprehensive 
analysis to date of the genetic alterations in PeCa and implicated novel somatic mutations in 
PeCa pathogenesis.  
 
PeCa appear genetically quiet with strikingly few recurrent somatic mutations identified 
when compared with other adult tumours. However, with the caveat that, as with many 
other exome sequencing projects, we are underpowered to detect low frequency (<10%) 
alterations.  The concept that PeCa are relatively genomically quiet, is further highlighted by 
the low number of copy number alterations seen in PeCa, with ~50% of PeCa showing no 
significant CNAs and only 13 regions of significant recurrent CNA (Figure S5). Although 
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analysis of the mutational spectrum suggests a ‘APOBEC’ mutational phenotype in HPV 
driven disease, as in other HPV driven tumours. The relative paucity of somatic alterations 
suggests that penile cancer development is driven by a complex interaction of molecular 
aberrations. The potential CpG deamination signature and concomitant reduction in DNA 
methylation in HPV negative tumours, suggests that changes to the epigenome may 
represent a major pathogenic mechanism in PeCa development(4).  
 
Analysis of recurrent somatic mutations identified novel candidate drivers in PeCa. These 
include the G Protein suppressor and member of the COP-9 signalosome complex, CSN1. The 
COP-9 complex and in particularly CSN1 has been implicated in the phosphorylation and 
activation of p53(19).  Previous screening studies in Drosophila identified other members of 
the COP-9 signalosome being involved in the miRNA pathway. Depletion of CSN3 and CSN7 
by RNAi in S2 cells led to increases in siRNA and miRNA-dependent silencing of reporter 
genes(20).  Dysregulation of the miRNA pathway is frequently observed in many cancers and 
further work is required to determine the mechanism by which single point mutations of 
CSN1 can disrupt miRNA-mediated silencing and define its role in the development of 
human malignancies. However, data presented here suggest CSN1 to be a novel tumour 
suppressor which when mutated disrupts miRNA-mediated gene silencing and thus 
contributes to the development of PeCa.  The identification of CSN1 mutation, and its role in 
aberrant miRNA processing, and that APOBEC family members also interact with AGO2 to 
inhibit miRNA-dependent silencing(21), suggest miRNA dysregulation may be an important 
driver of PeCa pathogenesis. 
 
We also observe the frequent mutation of the FAT1 tumour suppressor gene.  FAT1 is 
somatically altered (by mutation or deletion) in multiple tumour types. Here we show for 
the first time that in PeCa FAT1 is not only inactivated through somatic mutation but also 
through promoter hypermethylation, resulting in FAT1 deregulation in over a third of PeCa. 
This further highlights the potential important role of aberrant epigenetic changes in PeCa 
development.  
 
Our results, the first whole exome sequencing of penile cancer, provides novel insight into 
the relationship between somatic alterations and PeCa development. These data 
significantly enhance our current understanding of genetic alterations driving PeCa by 
showing that whilst recurrent somatic alterations can explain a proportion of PeCa, 
epigenetic mechanisms play a significant role in PeCa development. The discovery that 
mutations in the novel tumour suppressor gene CSN1, results in aberrant miRNA processing 
and the high rate of CpG deamination suggest that deregulated gene silencing and changes 
in epigenetic regulation play an important role in PeCa and particularly in non-HPV 
associated tumours.  
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Figure Legend 
Figure 1. Somatic variants in penile cancer. (a)Recurrently mutated genes in PeCa. The 
central heatmap shows the mutation status of the recurrently mutated genes for each 
tumour. Somatic mutations are colored according to functional class (lower panel). The left 
hand barplot shows the mutation count for each individual gene. The upper panel shows 
patient phenotype data for age, stage grade, Ti/Tv ratio and HPV viral status. (b) Schematic 
representation of the CSN1 protein. The conserved RPN7 and PCI domains are shown in blue 
and yellow respectively. CSN1 alterations, position and aa substitution are highlighted. Red – 
missense mutations.  
 
Figure 2. Mutational signatures in penile cancer. (a) Bar plot showing the breakdown of 
mutations by type of substitution reveals a high frequency of C>T and G>A mutations. (b) 
Boxplot of proportion of TCW alterations with patients stratified by HPV viral status (HPV 
High, HPV low and HPV negative),  
 
Figure 3. Mutations in CSN1 increase its localisation to Ago1 and 2 positive P-bodies and 
leads to inhibition of miR-100 and Let-7 dependent repression of gene expression. (a) The 
D355H and M357I mutations on CSN1 1 localise to both the nucleus of HeLa cells and to 
Ago1-YFP positive foci in the cytoplasm. Wild-type CSN1 localises predominantly to the 
nucleus with occasional foci being formed. (b) CSN1 mutants also localise to Ago2-YFP 
positive foci in cytoplasm. (c) Quantification of Ago positive foci co-localising with CSN1 
reveals the percentage of Ago positive foci co-localising with CSN1 is significantly increased 
with both mutants. Results presented as percentage change in co-localisation seen with 
wild-type. (d and e) miR-100 and let-7a reporter assays in HeLa cells show that 
overexpression of both D355H and M357I CSN1 mutants inhibit miRNA-dependent 
repression of a Renilla reporter gene containing miR-100 or let-7a binding sites in the 3’ UTR. 
Results are presented as a percentage change from repression in cells transfected with wild-
type CSN1. Wild-type CSN1 shows no significant difference from repression seen with empty 
vector. The activity of Renilla luciferase was assayed and normalized to firefly luciferase 
activity. Data are expressed relative to the activity of the reporter containing non-targeted 
miRNA sites. * means p < 0.05 according to student’s t-test.  
 



